Compare · ARAY vs DXCM
ARAY vs DXCM
Side-by-side comparison of Accuray Incorporated (ARAY) and DexCom Inc. (DXCM): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ARAY and DXCM operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- DXCM is the larger of the two at $28.11B, about 691.2x ARAY ($40.7M).
- Over the past year, ARAY is down 73.2% and DXCM is down 10.2% - DXCM leads by 63.0 points.
- DXCM has been more active in the news (26 items in the past 4 weeks vs 7 for ARAY).
- DXCM has more recent analyst coverage (25 ratings vs 4 for ARAY).
- Company
- Accuray Incorporated
- DexCom Inc.
- Price
- -
- -
- Market cap
- $40.7M
- $28.11B
- 1M return
- +15.91%
- +26.19%
- 1Y return
- -73.21%
- -10.22%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2007
- 2005
- News (4w)
- 7
- 26
- Recent ratings
- 4
- 25
Accuray Incorporated
Accuray Incorporated designs, develops, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the body in the Americas, Europe, the Middle East, India, Japan, Africa, and rest of the Asia Pacific region. The company offers the CyberKnife System, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of various types of cancer and tumors in the body. Its CyberKnife System automatically tracks, detects, and corrects for tumor and patient movement in real-time during the procedure, as well as enables the delivery of precise, high dose radiation while patients breathe normally. The company also offers the TomoTherapy System, including the Radixact System, which consists of an integrated and versatile radiation therapy system used for the treatment of a range of cancer types. It markets its products in the United States directly, as well as through sales organizations, sales agents, and group purchasing organizations; and directly, as well as through distributors and sales agents in Europe, Asia, and South America to hospitals and stand-alone treatment facilities. The company was incorporated in 1990 and is headquartered in Sunnyvale, California.
DexCom Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
Latest ARAY
- Accuray Incorporated filed SEC Form 8-K: Termination of a Material Definitive Agreement, Regulation FD Disclosure
- SEC Form 4 filed by SVP, Chief Commercial Officer Miele Paul Michael
- SEC Form SD filed by Accuray Incorporated
- Accuray Incorporated Reports Inducement Award Under NASDAQ Listing Rules
- SEC Form S-8 filed by Accuray Incorporated
- Amendment: SEC Form SCHEDULE 13D/A filed by Accuray Incorporated
- SEC Form 4 filed by Large owner Tcw Group Inc
- Accuray and the University of Wisconsin-Madison Announce Master Research Agreement to Improve Personalized Care for Patients with Cancer
- Accuray downgraded by BTIG Research
- SEC Form 10-Q filed by Accuray Incorporated
Latest DXCM
- Dexcom CONNECT Study: The Most Significant Clinical Study Demonstrating CGM Benefits for People with Type 2 Diabetes Not Using Insulin
- EVP, Chief Commercial Officer Coleman Jon sold $722,628 worth of shares (9,823 units at $73.56) as part of a pre-agreed trading plan, decreasing direct ownership by 9% to 95,450 units (SEC Form 4)
- Dexcom Reaffirms CGM Benefits for All People With Diabetes and Continues Momentum Toward Earlier Stage Intervention and Preventative Care at ADA 2026
- Dexcom Releases Customer Advisory Council Report, Outlining Ongoing Commitments to Enhancing Product Performance and User Experience
- Director Altman Steven R was granted 5,565 shares (SEC Form 4)
- Director Augustinos Nicholas was granted 5,575 shares (SEC Form 4)
- Director Malady Kyle was granted 5,575 shares, increasing direct ownership by 25% to 28,242 units (SEC Form 4)
- Director Heller Bridgette P was granted 5,575 shares, increasing direct ownership by 22% to 30,582 units (SEC Form 4)
- Director Osterloh Albert Frederick Iv was granted 1,630 shares, increasing direct ownership by 23% to 8,691 units (SEC Form 4)
- Director Foletta Mark G was granted 6,331 shares (SEC Form 4)